Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Activity of angiotensin-converting enzyme and risk of severe hypoglycaemia in type 1 diabetes mellitus

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Pedersen-Bjergaard, U ; Agerholm-Larsen, Birgit ; Pramming, S ; Hougaard, P ; Thorsteinsson, B. / Activity of angiotensin-converting enzyme and risk of severe hypoglycaemia in type 1 diabetes mellitus. In: Lancet. 2001 ; Vol. 357, No. 9264. pp. 1248-53.

Bibtex

@article{63a00f109b81424aa34d4b0f8a86b665,
title = "Activity of angiotensin-converting enzyme and risk of severe hypoglycaemia in type 1 diabetes mellitus",
abstract = "BACKGROUND: The insertion (I) allele of the angiotensin-converting-enzyme (ACE) gene occurs at increased frequency in endurance athletes. This association suggests that low ACE activity is favourable for performance in conditions with limited substrate availability. Such conditions occur in endurance athletes during competition and in diabetic patients during insulin-induced hypoglycaemia. Patients rely on preserved functional capacity to recognise hypoglycaemic episodes and avoid progression by self-treatment. We studied whether ACE activity is related to the risk of severe hypoglycaemia in type 1 diabetes.METHODS: Consecutive adult outpatients with type 1 diabetes, untreated with ACE inhibitors or angiotensin-II-receptor antagonists (n=207) reported their experience of mild and severe hypoglycaemia during the previous 1 year and 2 years. The patients were further characterised by diabetes history, degree of hypoglycaemia awareness, measurement of C-peptide, haemoglobin A(1c), and serum ACE concentrations, and determination of ACE genotype.FINDINGS: Patients with the DD genotype had a relative risk of severe hypoglycaemia in the preceding 2 years of 3.2 (95% CI 1.4-7.4) compared with those who had the II genotype. There was a significant relation between serum ACE activity and the rate of severe hypoglycaemia (relative risk per 10 U/L increment 1.4 [1.2-1.6]), corresponding to a 3.5 times higher risk for patients in the highest quartile than for those in the lowest quartile. Multiple regression analysis showed that the effect of the ACE genotype was explained by its influence on serum ACE activity and that the only other significant determinants of the risk of severe hypoglycaemia were the degree of hypoglycaemia awareness, b-cell function, and duration of diabetes of more than 20 years.INTERPRETATION: ACE activity is a clinically significant marker of the risk of severe hypoglycaemia in patients with type 1 diabetes, especially in those with impaired defence against hypoglycaemia. These findings need to be confirmed in prospective studies.",
keywords = "Adult, Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Diabetes Mellitus, Type 1, Female, Genotype, Hemoglobin A, Glycosylated, Humans, Hypoglycemia, Insulin, Male, Middle Aged, Peptidyl-Dipeptidase A, Polymerase Chain Reaction, Regression Analysis, Risk Factors, Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't",
author = "U Pedersen-Bjergaard and Birgit Agerholm-Larsen and S Pramming and P Hougaard and B Thorsteinsson",
year = "2001",
month = apr,
day = "21",
doi = "10.1016/S0140-6736(00)04405-6",
language = "English",
volume = "357",
pages = "1248--53",
journal = "The Lancet",
issn = "0140-6736",
publisher = "The/Lancet Publishing Group",
number = "9264",

}

RIS

TY - JOUR

T1 - Activity of angiotensin-converting enzyme and risk of severe hypoglycaemia in type 1 diabetes mellitus

AU - Pedersen-Bjergaard, U

AU - Agerholm-Larsen, Birgit

AU - Pramming, S

AU - Hougaard, P

AU - Thorsteinsson, B

PY - 2001/4/21

Y1 - 2001/4/21

N2 - BACKGROUND: The insertion (I) allele of the angiotensin-converting-enzyme (ACE) gene occurs at increased frequency in endurance athletes. This association suggests that low ACE activity is favourable for performance in conditions with limited substrate availability. Such conditions occur in endurance athletes during competition and in diabetic patients during insulin-induced hypoglycaemia. Patients rely on preserved functional capacity to recognise hypoglycaemic episodes and avoid progression by self-treatment. We studied whether ACE activity is related to the risk of severe hypoglycaemia in type 1 diabetes.METHODS: Consecutive adult outpatients with type 1 diabetes, untreated with ACE inhibitors or angiotensin-II-receptor antagonists (n=207) reported their experience of mild and severe hypoglycaemia during the previous 1 year and 2 years. The patients were further characterised by diabetes history, degree of hypoglycaemia awareness, measurement of C-peptide, haemoglobin A(1c), and serum ACE concentrations, and determination of ACE genotype.FINDINGS: Patients with the DD genotype had a relative risk of severe hypoglycaemia in the preceding 2 years of 3.2 (95% CI 1.4-7.4) compared with those who had the II genotype. There was a significant relation between serum ACE activity and the rate of severe hypoglycaemia (relative risk per 10 U/L increment 1.4 [1.2-1.6]), corresponding to a 3.5 times higher risk for patients in the highest quartile than for those in the lowest quartile. Multiple regression analysis showed that the effect of the ACE genotype was explained by its influence on serum ACE activity and that the only other significant determinants of the risk of severe hypoglycaemia were the degree of hypoglycaemia awareness, b-cell function, and duration of diabetes of more than 20 years.INTERPRETATION: ACE activity is a clinically significant marker of the risk of severe hypoglycaemia in patients with type 1 diabetes, especially in those with impaired defence against hypoglycaemia. These findings need to be confirmed in prospective studies.

AB - BACKGROUND: The insertion (I) allele of the angiotensin-converting-enzyme (ACE) gene occurs at increased frequency in endurance athletes. This association suggests that low ACE activity is favourable for performance in conditions with limited substrate availability. Such conditions occur in endurance athletes during competition and in diabetic patients during insulin-induced hypoglycaemia. Patients rely on preserved functional capacity to recognise hypoglycaemic episodes and avoid progression by self-treatment. We studied whether ACE activity is related to the risk of severe hypoglycaemia in type 1 diabetes.METHODS: Consecutive adult outpatients with type 1 diabetes, untreated with ACE inhibitors or angiotensin-II-receptor antagonists (n=207) reported their experience of mild and severe hypoglycaemia during the previous 1 year and 2 years. The patients were further characterised by diabetes history, degree of hypoglycaemia awareness, measurement of C-peptide, haemoglobin A(1c), and serum ACE concentrations, and determination of ACE genotype.FINDINGS: Patients with the DD genotype had a relative risk of severe hypoglycaemia in the preceding 2 years of 3.2 (95% CI 1.4-7.4) compared with those who had the II genotype. There was a significant relation between serum ACE activity and the rate of severe hypoglycaemia (relative risk per 10 U/L increment 1.4 [1.2-1.6]), corresponding to a 3.5 times higher risk for patients in the highest quartile than for those in the lowest quartile. Multiple regression analysis showed that the effect of the ACE genotype was explained by its influence on serum ACE activity and that the only other significant determinants of the risk of severe hypoglycaemia were the degree of hypoglycaemia awareness, b-cell function, and duration of diabetes of more than 20 years.INTERPRETATION: ACE activity is a clinically significant marker of the risk of severe hypoglycaemia in patients with type 1 diabetes, especially in those with impaired defence against hypoglycaemia. These findings need to be confirmed in prospective studies.

KW - Adult

KW - Angiotensin Receptor Antagonists

KW - Angiotensin-Converting Enzyme Inhibitors

KW - Diabetes Mellitus, Type 1

KW - Female

KW - Genotype

KW - Hemoglobin A, Glycosylated

KW - Humans

KW - Hypoglycemia

KW - Insulin

KW - Male

KW - Middle Aged

KW - Peptidyl-Dipeptidase A

KW - Polymerase Chain Reaction

KW - Regression Analysis

KW - Risk Factors

KW - Clinical Trial

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1016/S0140-6736(00)04405-6

DO - 10.1016/S0140-6736(00)04405-6

M3 - Journal article

C2 - 11418149

VL - 357

SP - 1248

EP - 1253

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9264

ER -

ID: 51548453